Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?

Galectin Therapeutics Ownership Summary

Galectin Therapeutics is owned by 8.65% institutional investors, 29.10% insiders, and 62.25% retail investors. Vanguard group is the largest institutional shareholder, holding 3.56% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.05% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Galectin Therapeutics	8.65%	29.10%	62.25%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	2.29M	3.56%	$9.52M
Blackrock	1.56M	2.52%	$3.53M
Marshall wace, llp	1.22M	1.91%	$3.40M
Advisor group	1.12M	1.76%	$3.13M
Blackrock funding, inc. /de	799.24K	1.25%	$2.23M
Millennium management	798.43K	1.25%	$2.23M
Wealthspire advisors	721.79K	1.13%	$2.01M
Geode capital management	612.79K	0.96%	$1.71M
Susquehanna group, llp	555.70K	0.87%	$1.55M
Two sigma investments, lp	467.06K	0.73%	$1.30M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Retirement guys formula	187.06K	0.24%	$521.90K
Solutions 4 wealth	25.03K	0.10%	$69.83K
Vivaldi capital management lp	258.58K	0.10%	$721.45K
Sovran advisors	257.83K	0.05%	$585.27K
Fortis capital advisors	106.14K	0.04%	$296.13K
Argyle capital partners	13.38K	0.03%	$37.32K
683 capital management	162.48K	0.02%	$453.33K
Wealthspire advisors	721.79K	0.02%	$2.01M
Geneos wealth management	240.93K	0.02%	$672.19K
Gsa capital partners llp	71.42K	0.01%	$199.00K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	1.56M	0.00%	851.14K
Marshall wace, llp	1.22M	0.00%	617.78K
Millennium management	798.43K	0.00%	562.93K
Two sigma investments, lp	467.06K	0.00%	450.45K
Vanguard fiduciary trust	304.24K	0.00%	304.24K

Top Sellers

Holder	Shares	% Assets	Change
Y-intercept (hong kong)	-	-	-235.19K
Atria wealth solutions	-	-	-186.00K
Morgan stanley	104.41K	-	-174.88K
Wellington management group llp	-	-	-142.22K
Soltis investment advisors	-	-	-140.75K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	304.24K	0.00%	304.24K	$848.83K
Renaissance	147.90K	0.00%	147.90K	$412.64K
Hrt financial lp	51.06K	0.00%	51.06K	$142.00K
Wiley bros.-aintree capital	41.00K	0.00%	41.00K	$114.39K
Brevan howard capital management lp	35.59K	0.00%	35.59K	$99.28K

Sold Out

Holder	Change
Eversource wealth advisors	-1.00
Sbi securities	-5.00
Legal & general group	-38.00
Srs capital advisors	-52.00
Sterling capital management	-74.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	44	-56.86%	5,526,312	-52.22%	8	2.67%	22	-59.26%	9	-59.09%
Dec 31, 2025	69	-22.47%	8,887,115	-13.85%	13	5.24%	32	-11.11%	17	-37.04%
Sep 30, 2025	87	-3.33%	10,009,146	-4.34%	15	5.76%	35	-5.41%	26	18.18%
Jun 30, 2025	88	-7.37%	9,965,158	0.59%	15	6.42%	36	24.14%	22	-26.67%
Mar 31, 2025	94	-14.55%	9,893,813	-1.83%	15	5.98%	30	-53.13%	29	222.22%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.35M	2.05%	-
Vanguard US Total Market Shares ETF	1.25M	1.97%	-
Vanguard Institutional Extnd Mkt Idx Tr	596.82K	0.91%	33.19K
Fidelity Extended Market Index	277.75K	0.42%	1.21K
Fidelity Small Cap Index	142.93K	0.23%	-17.81K
Extended Equity Market Fund E	127.99K	0.19%	-
Extended Equity Market Fund B	127.99K	0.19%	-
Blackrock Extended Mkt Fund CF	127.99K	0.19%	-
iShares Micro-Cap ETF	115.19K	0.17%	-
Extended Equity Market Fund K	108.98K	0.17%	-798.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 26, 2026	Jamil Khurram	Chief Medical Officer	Sell	$1.76K
Feb 06, 2026	ELDRED KARY	-	Buy	$810.00
Jan 02, 2026	LEWIS JOEL	President and CEO	Sell	$77.94K
Jan 06, 2026	LEWIS JOEL	President and CEO	Sell	$134.85K
Jan 05, 2026	LEWIS JOEL	President and CEO	Sell	$108.34K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	1
2026 Q1	1	9
2025 Q4	2	39
2025 Q3	2	2
2025 Q2	-	-

GALT Ownership FAQ

Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 8.65%, followed by 29.10% insiders and 62.25% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 35.75%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Vanguard group (2.29M shares, 3.56%), Blackrock (1.56M shares, 2.52%), and Marshall wace, llp (1.22M shares, 1.91%). Together, they hold 8.00% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Retirement guys formula is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.24% of its assets in 187.06K Galectin Therapeutics shares, valued at 521.9K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.05% of its total shares outstanding invested in 1.35M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools